Innæða krabbameinslyfjameðferð með slagæðastíflun: Árangur staðbundinnar krabbameinsmeðferðar á Íslandi
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2012-06
Metadata
Show full item recordOther Titles
Loco-regional therapy for liver malignancy in IcelandCitation
Læknablaðið 2012, 98(6):334-40Abstract
BACKGROUND AND AIMS: Transarterial chemoembolization (TACE) is a loco-regional therapy performed to treat tumors in the liver. The branch of the hepatic artery supplying the tumor is catheterized and a mixture of iodized oil, chemotherapeutic agents and PVA embolic materials infused. TACE is a palliative treatment of unresectable cancer in the liver but can also be employed as adjunctive therapy to liver resection and/or radiofrequency ablation. The procedure can in certain instances downstage the disease and provide a bridge to liver transplantation. The aim of this study was to evaluate outcome in patients that have undergone loco-regional therapy in Iceland and the frequency and severity of complications related to the procedure. MATERIAL AND METHODS: All Icelandic patients that had undergone TACE, transarterial chemotherapy or bland embolization of liver tumors between 1 May 2007 and 1 March 2011 were included in the study. RESULTS: Eighteen TACE, six transarterial chemotherapy treatments and two bland embolizations were performed on nine patients with hepatocellular carcinoma (HCC), and three patients with carcinoid metastases in the liver. Mean-survival of patients with HCC was 15.2 months. Survival of patients with carcinoid metastases was between 61 and 180 months. Complete response was achieved twice and partial response four times. The disease remained stable after eleven procedures but progressed after three procedures. Minor complications were diagnosed in 6 of 26 procedures and one major complication. No patient suffered from liver failure due to the procedure. Of the 9 HCC patients, 1 patient was on the liver transplant list before TACE and later underwent successful transplantation. Additionally, 3 of the remaining 8 patients were downstaged and put on to the transplant list.Inngangur: Innæðakrabbameinslyfjameðferð með slagæðastíflun er staðbundin krabbameinsmeðferð til að meðhöndla krabbamein í lifur. Meðferðin er líknandi en getur einnig nýst með skurðaðgerð og/eða rafbrennslu. Hún getur einnig nýst til að halda sjúklingum á lifrarígræðslulista eða niðurstiga sjúkdóminn svo þeir komist á slíkan lista. Markmið rannsóknarinnar var að kanna árangur staðbundinnar krabbameinsmeðferðar og tíðni fylgikvilla á Íslandi. Efni og aðferðir: Gerð var afturskyggn klínísk rannsókn sem náði til allra sem fengu innæðakrabbameinslyfjameðferð með slagæðastíflun, slagæðastíflanir og innæðakrabbameinslyfjagjafir á Íslandi frá 1. maí 2007 til 1. mars 2011. Upplýsingar voru fengnar úr sjúkraskrárkerfi og myndgeymslukerfi Landspítala. Niðurstöður: Það hafa verið framkvæmdar 18 innæðakrabbameinslyfjameðferðir með slagæðastíflun, 6 slagæðastíflanir og tvær svæðisbundnar krabbameinslyfjameðferðir til að meðhöndla 9 sjúklinga með lifrarfrumukrabbamein og þrjá með meinvörp frá krabbalíki. Meðallifun sjúklinga með lifrarfrumukrabbamein var 15,2 mánuðir og hjá sjúklingum með krabbalíkismeinvörp 61 til 180 mánuðir. Alger svörun varð tvisvar og hlutasvörun fjórum sinnum. Sjúkdómurinn hélst stöðugur í 11 skipti en versnaði í þremur tilvikum. Minniháttar fylgikvillar greindust eftir 6 af 26 inngripum. Einu sinni kom upp meiriháttar fylgikvilli. Enginn fékk lifrarbilun sem rekja má til inngripsins. Einn sjúklingur með lifrarfrumukrabbamein var á lifrarígræðslulista fyrir meðferð og tókst að halda honum á lista fram að ígræðslu. Þá tókst að niðurstiga þrjá svo þeir komust á listann. Ályktun: Árangur staðbundinnar krabbameinsmeðferðar er viðunandi hér á landi og eru fylgikvillar í kjölfar inngripsins innan marka.
Description
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/Open Allur texti - Full textAdditional Links
http://www. laeknabladid.isRights
Archived with thanks to LæknablađiđCollections
Related articles
- Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
- Authors: Seinstra BA, Defreyne L, Lambert B, Lam MG, Verkooijen HM, van Erpecum KJ, van Hoek B, van Erkel AR, Coenraad MJ, Al Younis I, van Vlierberghe H, van den Bosch MA
- Issue date: 2012 Aug 23
- Individualized treatment models based on blood supply characteristics in hepatocellular carcinoma using color Doppler hemodynamics.
- Authors: Si Q, Mu H, Yan G, Qian X, Xu C, Wang X, Tong W
- Issue date: 2007 Mar
- Current surgical treatment strategies for hepatocellular carcinoma in North America.
- Authors: Khan AS, Fowler KJ, Chapman WC
- Issue date: 2014 Nov 7
- Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
- Authors: Song MJ, Bae SH, Lee JS, Lee SW, Song DS, You CR, Choi JY, Yoon SK
- Issue date: 2016 Mar
- Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden.
- Authors: Ronot M, Cauchy F, Gregoli B, Breguet R, Allaham W, Paradis V, Soubrane O, Vilgrain V
- Issue date: 2016 Aug